Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Slides:

Advertisements

Similar presentations

Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.

Advertisements

YOUR CANCER TREATMENT: WHAT TO EXPECT FROM THE LATEST ADVANCEMENTS MIRIAM J. ATKINS, M.D.

Statistical Considerations for Safety Assessment in Cancer Immunotherapy Trials Andrew Lloyd Biometrics Manager PSI Conference May 2017.

Idelalisib plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

The Immune System. The Immune System Adaptive Immune Response.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

New Therapies for Hyperkalemia Across the Continuum of Care

New Patient Journeys in Non-small cell lung cancer

UNDERSTANDING RISK STRATIFICATION IN PAH:

Parkinson Disease:.

To Titrate or Not: Optimizing Treatment With Antiepileptic Drugs

Introduction to Checkpoint Inhibitors

Metastatic Renal Cell Carcinoma

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

The Tumor Microenvironment

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

The Art and Science of Diagnosing Seizures

Clinical Considerations in Evidence-based Management of GIST

Tailoring Hemophilia Prophylaxis Therapy

When Would You Use Single Inhaler Triple Therapy in COPD?

Faster-Acting Insulins

Optimizing Management of Advanced Bladder Cancer

Checkpoint Inhibition

Best Practices in Metastatic Colorectal Cancer

The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.

Checkpoint Inhibition

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Managing Adverse Events With New Oral Therapies in CLL

Optimizing Outcomes and Managing Adverse Events in CLL

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Management of Systematic Lupus Erythematosus

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Multidisciplinary Approaches to Managing Hemophilia

during cancer immunotherapy

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

The Changing Field of Melanoma: Ipilimumab.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Possible Causes of imAEs

Challenges and Opportunities

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Educational Objectives

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Pathogenesis of IBD, and the Role of Biologic Therapies

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in Evidence-based Management of GIST

The Nurse View: Spotlight on EGFR-Mutated NSCLC

A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

Moving Care Forward in Advanced Gastric Cancer

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.

Presentation transcript:

Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy

Overview of irAEs

Immune-Related Pneumonitis

Case Presentation: A 65-Year-Old Woman With Cough and Shortness of Breath

General Management Principles

General Management Principles (cont)

Pneumonitis

Grading Pneumonitis

Incidence of Pneumonitis

Timing of Onset Varies

Radiologic Features Vary

Case (cont)

Variable Pathologic Features

Early Management Algorithm

Immune-Related Toxicity Guidelines

Case (cont)

Ongoing Challenges With Anti-PD-1/PD-L1-Related Pneumonitis

Optimizing Immunosuppression for Anti-PD-1/PD-L1 Pneumonitis

Immune-Related Hepatitis

Case Presentation: A 55-Year-Old Woman With Elevated LFTs

Overview of Immune-Related Hepatitis

Screening for Immune-Related Hepatitis

Diagnosing Immune-Related Hepatitis

Grading Hepatitis Severity

Management of Grades 1 and 2 Hepatitis

Management of Grades 3 and 4 Hepatitis

Return to the Case

Steroid-Refractory Hepatitis

Case Conclusion

Immune-Related Colitis

Case Presentation: A 54-Year-Old Man With Diarrhea

How to Proceed?

Grading Diarrhea/Colitis

Working With Uncertainties

Return to the Case

Managing Diarrhea/Colitis

Notes on Tapering Steroids

Return to the Case

Return to the Case (cont)

Infliximab

Considering Endoscopy

Moving Forward

Overview of GI Toxicity

When Do GI irAEs Occur?

Abbreviations

Abbreviations (cont)